10 years of Keytruda and Opdivo

As the immunotherapies have won approval in other cancers over the years, they've also reset what doctors and patients alike think cancer care can do

Log In    Subscribe Oncology   After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do By Andrew Joseph Andrew Joseph / STAT The story — and the transformative impact — of immunotherapies like Bristol Myers Squibb's Opdivo and Merck's Keytruda are well known at this point. Yet, 10 years after their arrival, the field has also been in a moment of commemoration.   Recent data have prompted a once-unthinkable debate about how and when to declare a patient with metastatic melanoma cured. And as the immunotherapies have won approval in other cancers over the years, they've also reset what doctors and patients alike think cancer care can do. READ MORE Sign up for The Readout Your morning rundown of the science, politics, and money driving biotech today. In Case You Missed It An AstraZeneca win in bladder cancer, and more By Andrew Joseph Genentech, a biotech with a storied past, confronts new turbulence in the present By Jonathan Wosen Q&A: The U.S. can, and should, do more on H5N1 bird flu, a top WHO official says By Helen Branswell What the doctors' protests in India are missing By Kiran Kumbhar Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us